QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, M. Articles by Graves, L. M. Search for Related Content PubMed PubMed Citation Articles by Huang, M. Articles by Graves, L. M.

CELLULAR AND MOLECULAR

Inhibition of Nucleoside Transport by Protein Kinase Inhibitors

Department of Pharmacology (M.H., Y.W., L.M.G.) and the Lineberger Comprehensive Cancer Center (S.B.C., B.S.M.), University of North Carolina, Chapel Hill, North Carolina

Recently we reported that the pyridinylimidazole class of p38 mitogen-activated protein (MAP) kinase inhibitors potently inhibited the facilitated transport of nucleosides and nucleoside analogs in K562 cells. These compounds competed with the binding of nitrobenzylthioinosine (NBMPR) to K562 cells, consistent with inhibition of the NBMPR-sensitive equilibrative transporter (ENT1). In this study we examined a large number of additional protein kinase inhibitors for their effects on nucleoside transport. We find that incubation of K562 cells with tyrosine kinase inhibitors (AG825, AG1517, AG1478, STI-571), protein kinase C (PKC) inhibitors (staurosporine, GF 109203X, R0 31-8220, arcyriarubin A), cyclin-dependent kinase inhibitors (roscovitine, olomoucine, indirubin-3'-monoxime), or rapamycin resulted in a dose-dependent reduction of intracellular uptake of [³H]uridine. In contrast, neither the MAP kinase kinase inhibitors (U0126, PD 98059) nor the phosphatidyl inositol-3 kinase inhibitors (wortmannin, LY 294002) affected this process. Furthermore, both transient uptake and prolonged [³H]thymidine incorporation in K562 cells were inhibited by protein kinase inhibitors, inactive analogs of kinase inhibitors (R0 31-6045, SB202474), and NBMPR, independently of effects on cell proliferation as determined by MTT assay. These studies demonstrate that a wide variety of protein kinase inhibitors affect nucleoside uptake through selective inhibition of nucleoside transporters, independently of kinase inhibition.

This article has been cited by other articles:

				D. A. Reardon, M. J. Egorin, J. A. Quinn, J. N. Rich Sr, I. Gururangan, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, J. M. Provenzale, J. E. Herndon II, et al. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme J. Clin. Oncol., December 20, 2005; 23(36): 9359 - 9368. [Abstract] [Full Text] [PDF]

				C. Morel, G. Ibarz, C. Oiry, E. Carnazzi, G. Berge, D. Gagne, J.-C. Galleyrand, and J. Martinez Cross-interactions of Two p38 Mitogen-activated Protein (MAP) Kinase Inhibitors and Two Cholecystokinin (CCK) Receptor Antagonists with the CCK1 Receptor and P38 MAP Kinase J. Biol. Chem., June 3, 2005; 280(22): 21384 - 21393. [Abstract] [Full Text] [PDF]

				J. J. Gu, L. Santiago, and B. S. Mitchell Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl Blood, April 15, 2005; 105(8): 3270 - 3277. [Abstract] [Full Text] [PDF]

				P. Coy, R. Romar, R. R Payton, L. McCann, A. M Saxton, and J L. Edwards Maintenance of meiotic arrest in bovine oocytes using the S-enantiomer of roscovitine: effects on maturation, fertilization and subsequent embryo development in vitro Reproduction, January 1, 2005; 129(1): 19 - 26. [Abstract] [Full Text] [PDF]

				K. E. Hamden, P. W. Ford, A. G. Whitman, O. F. Dyson, S.-Y. Cheng, J. A. McCubrey, and S. M. Akula Raf-Induced Vascular Endothelial Growth Factor Augments Kaposi's Sarcoma-Associated Herpesvirus Infection J. Virol., December 1, 2004; 78(23): 13381 - 13390. [Abstract] [Full Text] [PDF]

				N. Chaudary, Z. Naydenova, I. Shuralyova, and I. R. Coe The Adenosine Transporter, mENT1, Is a Target for Adenosine Receptor Signaling and Protein Kinase C{epsilon} in Hypoxic and Pharmacological Preconditioning in the Mouse Cardiomyocyte Cell Line, HL-1 J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1190 - 1198. [Abstract] [Full Text] [PDF]